[Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
The novel principle of vaso-peptidase inhibition is based on the simultaneous inhibition of two enzymes, the angiotensin converting enzyme (ACE) and the neutral endopeptidase (NEP) by a single drug. NEP participates in metabolism of various natriuretic and vasodilatating peptides produced by atria and ventricles of the heart and endothelium (arterial natriuretic peptide, brain natriuretic peptide and C-Type natriuretic peptide). The orally effective vaso-peptidase inhibitor omapatrilate has recently become available. This substance reduced blood pressure in hypertensive patients in a dose-dependent fashion. It is tolerated as well as ACE inhibitors and seems to ameliorate mainly systolic pressure.
Waeber
B
B
Abteilung für Klinische Pathophysiologie und Medizinpädagogik, CHUV, Lausanne. bwaeber@chuv.hospvd.ch
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000201:enzymology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D015260:Neprilysin / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013841:Thiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011480:Protease Inhibitors; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D008666:Metalloendopeptidases; D015260:Neprilysin